Compare Nuwellis Inc (NUWE) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Verisign, Inc. — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Verisign, Inc. trades at $305.75 (market cap $26.92B). The key difference: Verisign, Inc. is far larger — about 12236.4× Nuwellis Inc's market cap, and Verisign, Inc. pays a 1.09% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Verisign, Inc. for 123 Days on average.
| NUWE | VRSN | |
|---|---|---|
Market Cap | $2.20M | $26.92B |
Volume | 121,544 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $146.65 | $310.00 |
52-Week Low | $0.68 | $211.49 |
Typical Hold Time | 26 Days | 123 Days |
Enterprise Value | -$1.52M | $28.23B |
Dividend Yield | — | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
VeriSign (VRSN) trades at $301.59, up 2.5% today, with a bullish technical signal and strong institutional buying. The company reported robust Q2 2026 earnings with revenue up 6% year-over-year and EPS of $2.38, though it missed expectations. High profitability is evident with a net income margin near 50%, and cash flow trends are improving. Recent news includes a class-action antitrust lawsuit and insider selling by the CEO, but analyst consensus remains positive.
The outlook is supported by solid fundamentals and a consensus price target of $348, offering ~15% upside. Key risks include legal challenges from the antitrust suit and reliance on domain registration growth. Earnings momentum and institutional accumulation provide tailwinds, but investors should weigh litigation risks against the company's stable cash flows and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
